Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: A systematic review and meta-analysis

Annals of Surgery

Volumn 261, Issue 3, 2015, Pages 421-429

  Müller Stich, Beat P ^a   Senft, Jonas D ^a   Warschkow, René ^b,d   Kenngott, Hannes G ^a   Billeter, Adrian T ^a   Vit, Gianmatteo ^a   Helfert, Stefanie ^a   Diener, Markus K ^a,c   Fischer, Lars ^a   Büchler, Markus W ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Medical Informatics and Biometry   (Germany)

^c Study Center of the German Surgical Society (SDGC)   (Germany)

^d Department of Internal Medicine I and Clinical Chemistry University of Heidelberg ^*  (Switzerland)

Author keywords

Bariatric surgery; Diabetes; Diabetes mellitus; Gastric bypass; Metaanalysis; Metabolic surgery; RYGB; T2DM

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C;

BARIATRIC SURGERY; BODY MASS; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPARATIVE EFFECTIVENESS; DIABETIC OBESITY; DIABETIC PATIENT; DYSLIPIDEMIA; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; COMPLICATION; DIABETES MELLITUS, TYPE 2; MORBID OBESITY; OBESITY;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; OBESITY, MORBID;

EID: 84926679649     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001014     Document Type: Review

References (56)

1. German Diabetes Association, Matthaei S, Bierwirth R, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: Update of the evidencebased guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes. 2009;117: 522-557.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35: 1364-1379.
3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291: 335-342.
4. SAGES Guidelines Committee. SAGES guideline for clinical application of laparoscopic bariatric surgery. Surg Obes Relat Dis. 2009;5: 387-405.
5. Runkel N, Colombo-Benkmann M, Hüttl TP, et al. Evidence-based German guidelines for surgery for obesity. Int J Colorectal Dis. 2011;26: 397-404.
6. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122: 248-256.e5.
7. Boza C, Muñoz R, Salinas J, et al. Safety and efficacy of Roux-en-Y gastric bypass to treat type 2 diabetes mellitus in non-severely obese patients. Obes Surg. 2011;21: 1330-1336.
8. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351: 2683-2693.
9. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patientswith diabetes. N Engl JMed. 2012;366: 1567-1576.
10. Lee W-J, Chong K, Chen C-Y, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index <35 kg/m2 Obes Surg. 2011 21 889-895
11. Bose M, Teixeira J, Olivan B, et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. JDiabetes. 2010;2: 47-55.
12. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA. 2008;299: 316-323.
13. Demaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg. 2010;252: 559-566; discussion 566-567.
14. Ikramuddin S, Korner J, LeeW-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309: 2240-2249.
15. Cummings DE, Cohen RV. Beyond BMI: The need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2: 175-181.
16. Bays HE, Chapman RH, Grandy S, et al. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: Comparison of data from two national surveys. Int J Clin Pract. 2007;61: 737-747.
17. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA. 2013;309: 2250-2261.
18. Parikh M, Issa R, Vieira D, et al. Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: A systematic review and meta-analysis. J Am Coll Surg. 2013;217: 527-532.
19. Reis CEG, Alvarez-Leite JI, Bressan J, et al. Role of bariatric-metabolic surgery in the treatment of obese type 2 diabetes with body mass index <35 kg/m2: A literature review Diabetes Technol Ther. 2012 14 365-372
20. Li Q, Chen L, Yang Z, et al. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index <35 kg/m2. Diabetes Obes Metab. 2012;14:262-270.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8: 336-341.
22. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of metaanalyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354: 1896-1900.
23. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52: 377-384.
24. SchulzKF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias.Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: 408-412.
25. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5: 13.
26. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available at: Www.cochrane-handbook.org. Accessed June 26, 2014.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7: 177-188.
28. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21: 1539-1558.
29. Whitehead A, Whitehead J.Ageneral parametric approach to themeta-analysis of randomized clinical trials. Stat Med. 1991;10: 1665-1677.
30. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295: 676-680.
31. Duval S, Tweedie R. Trim and fill: Asimple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56: 455-463.
32. Senn S, Gavini F, Magrez D, et al. Issues in performing a network metaanalysis. Stat Methods Med Res. 2013;22: 169-189.
33. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes -3-year outcomes. N Engl JMed. 2014;370: 2002-2013.
34. Wentworth JM, Playfair J, Laurie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: A randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2: 545-552.
35. Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetesmellituswith hypertension: Arandomized controlled trial. Diabetes Res Clin Pract. 2013;101: 50-56.
36. Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: A randomized clinical trial. JAMA Surg. 2014;149: 707-715.
37. Halperin F, Ding S-A, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: Feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149: 716-726.
38. Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253: 699-703.
39. Serrot FJ, Dorman RB, Miller CJ, et al. Comparative effectiveness of bariatric surgery and nonsurgical therapy in adults with type 2 diabetes mellitus and body mass index < 35 kg/m2 Surgery. 2011 150 684-691
40. Chiellini C, Rubino F, Castagneto M, et al.The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2. Diabetologia. 2009;52: 1027-1030.
41. Geloneze B, Geloneze SR,Chaim E, et al.Metabolic surgery for non-obese type 2 diabetes: Incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg. 2012;256:72-78.
42. Abbatini F, Capoccia D, Casella G, et al. Type 2 diabetes in obese patients with body mass index of 30-35 kg/m2: Sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis. 2012;8: 20-24.
43. Scopinaro N, Adami GF, Papadia FS, et al. Effects of gastric bypass on type 2 diabetes in patients with BMI 30 to 35. Obes Surg. 2014;24: 1036-1043.
44. Müller-Stich BP, Fischer L, Kenngott HG, et al. Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization-results of a prospective cohort study (DiaSurg 1 study). Ann Surg. 2013;258: 760-765; discussion 765-766.
45. DePaula AL, Macedo ALV, Mota BR, et al. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc. 2009;23: 1313-1320.
46. Thomas RL, Prior SL, Barry JD, et al. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. J Diabetes Complicat. 2014;28: 191-195.
47. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509: 183-188.
48. Mencarelli A, Renga B, D'Amore C, et al. Dissociation of intestinal and hepatic activities of FXR and LXR supports metabolic effects of terminal ileum interposition in rodents. Diabetes. 2013;62: 3384-3393.
49. Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18: 950-955.
50. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36: 1859-1864.
51. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347: F5934.
52. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253: 484-487.
53. Mäklin S, Malmivaara A, Linna M, et al. Cost-utility of bariatric surgery for morbid obesity in Finland. Br J Surg. 2011;98: 1422-1429.
54. Brethauer SA, AminianA, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258: 628-636; discussion 636-637.
55. Lee W-J, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: Age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9: 379-384.
56. Kenngott HG, Clemens G, Gondan M, et al. DiaSurg 2 trial-surgical vs. medical treatment of insulin-dependent type 2 diabetesmellitus in patientswith a body mass index between 26 and 35 kg/m2: Study protocol of a randomized controlled multicenter trial-DRKS00004550. Trials. 2013;14: 183.